Form 4 Emergent Biosolutions Inc For: 2 July
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Emergent Biosolutions Inc (EBS)
Emergent Biosolutions Inc stock price live, this page displays NYSE EBS stock exchange data. View the EBS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Emergent Biosolutions Inc real time stock price chart below.
What Is the Emergent Biosolutions Inc Stock Price Today?
The Emergent Biosolutions Inc stock price today is 7.260.
What Is the Stock Symbol for Emergent Biosolutions Inc?
The stock symbol for Emergent Biosolutions Inc is "EBS."
What Stock Exchange Does Emergent Biosolutions Inc Trade On?
Emergent Biosolutions Inc is listed and trades on the NYSE stock exchange.
Is Emergent Biosolutions Inc a Good Stock to Buy?
Determining whether Emergent Biosolutions Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EBS quote. (ISIN: US29089Q1058)
What Is the Emergent Biosolutions Inc Stock Price Today?
The Emergent Biosolutions Inc stock price today is 7.260.
What Is the Stock Symbol for Emergent Biosolutions Inc?
The stock symbol for Emergent Biosolutions Inc is "EBS."
What Stock Exchange Does Emergent Biosolutions Inc Trade On?
Emergent Biosolutions Inc is listed and trades on the NYSE stock exchange.
Is Emergent Biosolutions Inc a Good Stock to Buy?
Determining whether Emergent Biosolutions Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EBS quote. (ISIN: US29089Q1058)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.190
7.450
52 wk Range
5.615
14.060
Earnings results expected in 6 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.1907.450
52 wk Range
5.61514.060
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EBS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
12.000
Upside
+65.29%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 12.000
(+65.29% Upside)
Emergent Biosolutions Inc Earnings Call Summary for Q1/2026
- Q1 2026 revenue hit $156M, exceeding guidance of $135M-$155M, driven by Medical Countermeasures and naloxone franchise performance.
- Adjusted EBITDA reached $36M with 23% margin; operating expenses declined $10M year-over-year; net debt reduced by $122M versus Q1 2025.
- Stock rose 2.38% to $8.18 in aftermarket trading but remains well below 52-week high of $14.06, trading at P/E ratio of 8.93.
- Company forecasts negative EPS for FY 2027, citing market saturation risks and macro-economic pressures on government contracts.
- CEO Papa emphasized diversified portfolio strength; CFO Lindahl highlighted continued debt reduction focus and strategic partnerships for growth.
Last Updated: 2026-04-30, 05:52 p/m
Read Full TranscriptEarnings
Latest Release
Apr 30, 2026
EPS / Forecast
0.21 / 0.86
Revenue / Forecast
156.1M / 205M
Compare EBS to Peers and Sector
Metrics to compare | EBS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEBSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −44.1x | −4.6x | −0.3x | |
PEG Ratio | −0.48 | −0.23 | 0.00 | |
Price/Book | 0.7x | 3.5x | 2.6x | |
Price / LTM Sales | 0.6x | 4.2x | 2.9x | |
Upside (Analyst Target) | 63.3% | 64.3% | 56.7% | |
Fair Value Upside | Unlock | −0.1% | 10.2% | Unlock |
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Emergent Biosolutions (EBS) Stock Price Today?
The Emergent Biosolutions stock price today is 7.260 USD.
What Stock Exchange Does Emergent Biosolutions Trade On?
Emergent Biosolutions is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Emergent Biosolutions?
The stock symbol for Emergent Biosolutions is "EBS."
What Is the Emergent Biosolutions Market Cap?
As of today, Emergent Biosolutions market cap is 379.230M USD.
What Is Emergent Biosolutions's Earnings Per Share (TTM)?
The Emergent Biosolutions EPS (TTM) is -0.213.
When Is the Next Emergent Biosolutions Earnings Date?
Emergent Biosolutions will release its next earnings report on Aug 05, 2026.
From a Technical Analysis Perspective, Is EBS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Emergent Biosolutions Stock Split?
Emergent Biosolutions has split 0 times.
How Many Employees Does Emergent Biosolutions Have?
Emergent Biosolutions has 900 employees.
What is the current trading status of Emergent Biosolutions (EBS)?
As of Jul 30, 2026, Emergent Biosolutions (EBS) is trading at a price of 7.260 USD, with a previous close of 7.350 USD. The stock has fluctuated within a day range of 7.190 USD to 7.450 USD, while its 52-week range spans from 5.615 USD to 14.060 USD.
What Is Emergent Biosolutions (EBS) Price Target According to Analysts?
The average 12-month price target for Emergent Biosolutions is 12.000 USD, with a high estimate of 12 USD and a low estimate of 12 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +65.29% Upside potential.
What Is the EBS Premarket Price?
EBS's last pre-market stock price is 7.170 USD. The pre-market share volume is 10.000, and the stock has decreased by -0.180, or -2.450%.
What Is the EBS After Hours Price?
EBS's last after hours stock price is 7.300 USD, the stock has decreased by 0.040, or 0.550%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.